MétaCan
Menu
Back to cohort
Record W1965717563 · doi:10.1002/cpt.59

From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients

2015· article· en· W1965717563 on OpenAlexaff
H‐G Eichler, LG Baird, Richard Barker, Brigitte Bloechl‐Daum, Finn Børlum Kristensen, Jeffrey S. Brown, Rachel Chua, Susanna Del Signore, Ute Dugan, John Ferguson, S Garner, Wim Goettsch, Jeremy R.M. Haigh, Peter K. Honig, Anton Hoos, P Huckle, Tatsuya Kondo, Yann Le Cam, Hubert G. M. Leufkens, Robyn Lim, Carole Longson, Murray Lumpkin, John M. Maraganore, Brian O’Rourke, Kenneth A. Oye, Edmund J. Pezalla, Francesco Pignatti, June Raine, Guido Rasi, Tomas Salmonson, Dima Samaha, Sebastian Schneeweiß, PD Siviero, Matthew Skinner, J. Russell Teagarden, Toshiyoshi Tominaga, MR Trusheim, Sean Tunis, T F Unger, Spiros Vamvakas, Gigi Hirsch

Bibliographic record

VenueClinical Pharmacology & Therapeutics · 2015
Typearticle
Languageen
FieldEconomics, Econometrics and Finance
TopicHealth Systems, Economic Evaluations, Quality of Life
Canadian institutionsInstitut National d'Excellence en Santé et en Services SociauxCanadian Agency for Drugs and Technologies in HealthHealth Canada
FundersEuropean Federation of Pharmaceutical Industries and Associations
KeywordsRisk analysis (engineering)SustainabilityBusinessDrug developmentLife spanAdaptive strategiesNew product developmentMedicineDrugMarketingGerontologyPharmacology

Abstract

fetched live from OpenAlex

The concept of adaptive licensing (AL) has met with considerable interest. Yet some remain skeptical about its feasibility. Others argue that the focus and name of AL should be broadened. Against this background of ongoing debate, we examine the environmental changes that will likely make adaptive pathways the preferred approach in the future. The key drivers include: growing patient demand for timely access to promising therapies, emerging science leading to fragmentation of treatment populations, rising payer influence on product accessibility, and pressure on pharma/investors to ensure sustainability of drug development. We also discuss a number of environmental changes that will enable an adaptive paradigm. A life-span approach to bringing innovation to patients is expected to help address the perceived access vs. evidence trade-off, help de-risk drug development, and lead to better outcomes for patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.021
metaresearch head score (Gemma)0.049
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Theoretical or conceptual · Consensus signal: Theoretical or conceptual
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.021
Threshold uncertainty score0.111

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0210.049
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0010.008
Scholarly communication0.0060.017
Open science0.0020.009
Research integrity0.0050.007
Insufficient payload (model declined to judge)0.0160.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.697
GPT teacher head0.502
Teacher spread0.194 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designTheoretical or conceptual
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations187
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueClinical Pharmacology & TherapeuticsSame topicHealth Systems, Economic Evaluations, Quality of LifeFrench-language works237,207